24HourWire
News from all angles
STAT News
Center
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.